Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

Clinical Evidence That Deficiency of the Methylcytosine Dioxygenase TET2 Gene Promotes the Clonal Expansion and Therapeutic Efficacy of CD19-Directed T Cells

Blood (2017) 130 (Supplement 1): 1909.

https://doi.org/10.1182/blood.V130.Suppl_1.1909.1909

Published: 2017

Journal Articles

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

Marco Ruella, MD, Saad S Kenderian, MD, Olga Shestova, PhD, Joseph A. Fraietta, PhD, Sohail Qayyum, MD, Qian Zhang, MD PhD, Marcela V. Maus, MDPhD, Xiaobin Liu, PhD, Selene Nunez-Cruz, PhD, Michael Klichinsky, PharmD, Omkar Uday Kawalekar, MS, BS, Michael C. Milone, MD PhD, Simon F. Lacey, PhD BSc, Anthony Mato, MD, Stephen J. Schuster, MD, Michael Kalos, PhD, Carl H. June, MD, Saar I Gill, MBBS, PhD, Mariusz A. Wasik, MD

Blood (2015) 126 (23): 704.

https://doi.org/10.1182/blood.V126.23.704.704

Published: 2015

Journal Articles

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

Michael A. Pulsipher, Chris Carlson, Bryan Langholz, Donna A. Wall, Kirk R. Schultz, Nancy Bunin, Ilan Kirsch, Julie M. Gastier-Foster, Michael Borowitz, Cindy Desmarais, David Williamson, Michael Kalos, Stephan A. Grupp

Blood (2015) 125 (22): 3501–3508.

https://doi.org/10.1182/blood-2014-12-615757

Published: 2015

Includes: Supplemental data

Journal Articles

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Marco Ruella, MD, David Barrett, MD PhD, Saad S. Kenderian, MD, Olga Shestova, PhD, Ted J. Hofmann, PhD, John Scholler, Simon F. Lacey, PhD BSc, Jan J Melenhorst, PhD, Farzana Nazimuddin, MS, Michael Kalos, PhD, David L. Porter, MD, Carl H. June, MD, Stephan A. Grupp, MD PhD, Saar I. Gill, MD PhD

Blood (2014) 124 (21): 966.

https://doi.org/10.1182/blood.V124.21.966.966

Published: 2014

Journal Articles

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Blood (2014) 124 (21): 1982.

https://doi.org/10.1182/blood.V124.21.1982.1982

Published: 2014

Journal Articles

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Blood (2014) 124 (21): 1983.

https://doi.org/10.1182/blood.V124.21.1983.1983

Published: 2014

Journal Articles

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Saar Gill, Sarah K. Tasian, Marco Ruella, Olga Shestova, Yong Li, David L. Porter, Martin Carroll, Gwenn Danet-Desnoyers, John Scholler, Stephan A. Grupp, Carl H. June, Michael Kalos

Blood (2014) 123 (15): 2343–2354.

https://doi.org/10.1182/blood-2013-09-529537

Published: 2014

Includes: Supplemental data

Journal Articles

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A. Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemison, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2013) 122 (21): 4162.

https://doi.org/10.1182/blood.V122.21.4162.4162

Published: 2013

Journal Articles

Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses

Blood (2013) 122 (21): 766.

https://doi.org/10.1182/blood.V122.21.766.766

Published: 2013

Journal Articles

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

David L. Porter, MD, Michael Kalos, PhD, Noelle V. Frey, MD, Stephan A Grupp, MD, PhD, Alison W. Loren, MD, Christina Jemision, RN, Joan Gilmore, Holly McConville, RN, BSN, James Capobianchi, Lester Lledo, CRNP, Anne Chew, PhD, Angela Shen, MD, Patricia A. Wood, MD, PhD, Manuel Litchman, MD, Zhaohui Zheng, Bruce L. Levine, PhD, Carl H. June, MD

Blood (2013) 122 (21): 873.

https://doi.org/10.1182/blood.V122.21.873.873

Published: 2013

Journal Articles

Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study

Michael A. Pulsipher, MD, Christopher S Carlson, PhD, Krailo Mark, PhD, Donna A. Wall, MD, Kirk R. Schultz, MD, Nancy Bunin, MD, Michael Kalos, PhD, Desmarias Cindy, PhD, David Williamson, PhD, Gastier-Foster Julie, MD, PhD, Michael J. Borowitz, MD, PhD, Stephan A. Grupp, MD, PhD

Blood (2013) 122 (21): 919.

https://doi.org/10.1182/blood.V122.21.919.919

Published: 2013

Journal Articles

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Stephan A Grupp, MD, PhD, Noelle V. Frey, MD, Richard Aplenc, MD, PhD, David M Barrett, MD/PhD, Anne Chew, PhD, Michael Kalos, PhD, Bruce L. Levine, PhD, Manuel Litchman, MD, Shannon L Maude, MD, PhD, Susan R. Rheingold, Angela Shen, MD, Christine Strait, David T. Teachey, MD, Patricia A. Wood, MD, PhD, David Porter, MD, Carl H. June, MD

Blood (2013) 122 (21): 67.

https://doi.org/10.1182/blood.V122.21.67.67

Published: 2013

Journal Articles

Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19

Michael Kalos, PhD, Farzana Nazimuddin, Jeffrey M. Finklestein, Minnal Gupta, Irina Kulikovskaya, David E. Ambrose, Saar Gill, MD, PhD, Simon F. Lacey, PhD, BSc, Zhaohui Zheng, J. Joseph. Melenhorst, PhD, Bruce L. Levine, PhD, Noelle V. Frey, MD, Stephan A. Grupp, MD, PhD, David L. Porter, MD, Carl H. June, MD

Blood (2013) 122 (21): 163.

https://doi.org/10.1182/blood.V122.21.163.163

Published: 2013

Journal Articles

Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models

Saar Gill, MD, PhD, Sarah K Tasian, MD, Marco Ruella, MD, Olga Shestova, PhD, Yong Li, MD, MS, David L. Porter, MD, Martin Carroll, MD, Gwenn Danet-Desnoyers, PhD, John Scholler, Stephan A Grupp, MD, PhD, Carl H. June, MD, Michael Kalos, PhD

Blood (2013) 122 (21): 143.

https://doi.org/10.1182/blood.V122.21.143.143

Published: 2013

Journal Articles

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Blood (2013) 122 (6): 863–871.

https://doi.org/10.1182/blood-2013-03-490565

Published: 2013

Includes: Supplemental data

Journal Articles

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

David T. Teachey, Susan R. Rheingold, Shannon L. Maude, Gerhard Zugmaier, David M. Barrett, Alix E. Seif, Kim E. Nichols, Erica K. Suppa, Michael Kalos, Robert A. Berg, Julie C. Fitzgerald, Richard Aplenc, Lia Gore, Stephan A. Grupp

Blood (2013) 121 (26): 5154–5157.

https://doi.org/10.1182/blood-2013-02-485623

Published: 2013

Includes: Supplemental data

Journal Articles

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV

Blood (2013) 121 (9): 1524–1533.

https://doi.org/10.1182/blood-2012-07-447250

Published: 2013

Includes: Supplemental data

Journal Articles

Immune Profiling Suggests an IGH Signaling-Dependent Subtype of Aggressive B-ALL

Christopher S Carlson, PhD, Michael A. Pulsipher, MD, Bryan Langholz, PhD, Anna Sherwood, PhD, Cindy Desmarais, PhD, Harlan Robins, PhD, Michael Kalos, PhD, Stephan A. Grupp, MD, PhD

Blood (2012) 120 (21): 1428.

https://doi.org/10.1182/blood.V120.21.1428.1428

Published: 2012

Journal Articles

CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).

Stephan A. Grupp, MD, PhD, David L Porter, MD, David T Teachey, MD, David M. Barrett, MD/PhD, Anne Chew, PhD, Erica Suppa, Bruce L. Levine, PhD, Michael Kalos, PhD, Carl H. June, MD

Blood (2012) 120 (21): 2604.

https://doi.org/10.1182/blood.V120.21.2604.2604

Published: 2012

Journal Articles

Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT

Blood (2012) 120 (21): 472.

https://doi.org/10.1182/blood.V120.21.472.472

Published: 2012

NARROW

Clinical Evidence That Deficiency of the Methylcytosine Dioxygenase TET2 Gene Promotes the Clonal Expansion and Therapeutic Efficacy of CD19-Directed T Cells

The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma

IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients

Novel Chimeric Antigen Receptor T Cells for the Treatment of CD19-Negative Relapses Occurring after CD19-Targeted Immunotherapies

Randomized, Phase II Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed, Refractory CLL

Cytokine Release Syndrome (CRS) after Chimeric Antigen Receptor (CAR) T Cell Therapy for Relapsed/Refractory (R/R) CLL

Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor–modified T cells

Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019 cells) Have Long-Term Persistence and Induce Durable Responses In Relapsed, Refractory CLL

Engineered T-Cells Expressing An HLA-Restricted Affinity-Enhanced TCR In Advanced Multiple Myeloma Patients Post Auto-SCT Engraft and Are Associated With Encouraging Post Auto-SCT Responses

Randomized, Phase II Dose Optimization Study Of Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) In Patients With Relapsed, Refractory CLL

Striking Predictive Power For Relapse and Decreased Survival Associated With Detectable Minimal Residual Disease by IGH VDJ Deep Sequencing Of Bone Marrow Pre- and Post-Allogeneic Transplant In Children With B-Lineage ALL: A Subanalysis Of The COG ASCT0431/PBMTC ONC051 Study

T Cells Engineered With a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Produce Significant In Vivo Proliferation, Complete Responses and Long-Term Persistence Without Gvhd In Children and Adults With Relapsed, Refractory ALL

Long-Term Functional Persistence, B Cell Aplasia and Anti-Leukemia Efficacy In Refractory B Cell Malignancies Following T Cell Immunotherapy Using CAR-Redirected T Cells Targeting CD19

Anti-CD123 Chimeric Antigen Receptor T Cells (CART-123) Provide A Novel Myeloablative Conditioning Regimen That Eradicates Human Acute Myeloid Leukemia In Preclinical Models

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma

Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy

Antiviral effects of autologous CD4 T cells genetically modified with a conditionally replicating lentiviral vector expressing long antisense to HIV

Immune Profiling Suggests an IGH Signaling-Dependent Subtype of Aggressive B-ALL

CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).

Adoptive Transfer of Gene-Modified T-Cells Engineered to Express High-Affinity TCRs for Cancer-Testis Antigens (CTAs) NY-ESO-1 or Lage-1, in MM Patients Post Auto-SCT

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only